
In a blow to its diabetes pipeline, Sanofi has withdrawn a new drug application (NDA) for lixisenatide in the US …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

